[Yokohama, Japan, August 3-5, 2023] - SeekIn Inc., a leading biotechnology company focused on innovative cancer detection and patient prognosis solutions, announces its participation in the prestigious ASCO Breakthrough Conference. The event takes place in Yokohama Japan on August 3-5, 2023.
SeekIn Inc. presents three groundbreaking posters during Poster Session A. The sessions feature cutting-edge research and advancements in the field of cancer detection and treatment response prediction:
• Abstract Title: "A Panel of Seven Protein Tumour Markers for Effective and Affordable Multi-Cancer Early Detection by Artificial Intelligence" (Abstract ID: 155)
• Presenter: [Dr. Mao]
• Abstract Title: "Prospective Study to Assess Treatment Response and Predict Patient Prognosis by a Blood-Based Multi-Omics Assay in Lymphoma Patients" (Abstract ID: 116)
• Presenter: [Dr. Mao]
• Abstract Title: "Integrating Multi-Omics Features for Blood-Based Multi-Cancer Early Detection" (Abstract ID: 156)
• Presenter: [Dr. Mao]
The first abstract focuses on the groundbreaking work of SeekIn's artificial intelligence-driven approach to detect multiple cancer types at early stage through a panel of seven protein tumor markers. This innovative method aims to make cancer screening both effective and affordable.
The second abstract presents a prospective study that utilizes SeekInClarity®, a pan-cancer, non-invasive efficacy detection technology, to evaluate treatment response and prognosis prediction in lymphoma patients . This study demonstrated that, compared with traditional imaging methods, peripheral blood-based test SeekInClarity® is a non-invasive and more sensitive detection method that allows real-time quantitative monitoring. In addition, SeekInClarity® enables the monitoring of a wide range of tumors by comprehensively evaluating multiple specific cancer molecular indicators in the genome and proteome.
SeekIn's pioneering research in this area is expected to significantly improve patient prognosis and treatment decision-making.
The last abstract highlights SeekIn's integration of multi-omics features for blood-based multi-cancer early detection.
In this study, we provided a non-invasive MCED test (SeekInCare®) based on multi-omics and multi-dimensional features, and the results showed that SeekInCare® performed quite well in lymphoma with a sensitivity of 69.4% and a specificity 98.0%. It suggested that this is an efficient, non-invasive and economical method for lymphoma detection. In addition, the SeekInCare® test is not limited to lymphoma, it can also detect more than 20 cancer types simultaneously. The excellent performance of SeekInCare® in the real world makes a strong case for its future utility and affordability as a large-scale early detection of cancer in the average-risk populations.
The company's advanced technology has made exciting progress in identifying cancer at earlier stages, thereby drastically improving patient survival rates.
As a leading presenter at ASCO Breakthrough Conference, SeekIn Inc. is excited to share its groundbreaking research and contribute to the advancement of cancer diagnostics and personalized treatment strategies.